REGULATORY

Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions

By Ken Yoshino December 5, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) on December 4 kicked off discussions on the product coverage and rules to be applied for the next “off-year” drug price revision slated for FY2025. While payers were in lockstep seeking revisions on…

To read the full story

MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
December 19, 2024

REGULATORY

LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…